Cantor Fitzgerald tells investors in a research note that shares of EyePoint were weak after the company announced the appointment of Ramiro Ribeiro as chief medical officer, succeeding Dario Paggiarino, who has served as CMO since 2016. The firm views the hire as an incremental positive and would buy shares on the weakness, especially with the company’s next data readout around the corner in 2Q24. The firm made no change to its Overweight rating or $28 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EYPT:
- EyePoint appoints Ribeiro as Chief Medical Officer
- EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
- EYPT Upcoming Earnings Report: What to Expect?
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
